Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
NCT01933711
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
328
Enrollment
OTHER
Sponsor class
Conditions
CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma
Interventions
DRUG:
rituximab
Sponsor
University Hospital Heidelberg